Literature DB >> 19850470

Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.

Roderick Skinner1, Annie Parry, Lisa Price, Michael Cole, Alan W Craft, Andrew D J Pearson.   

Abstract

PURPOSE: The long-term outcome of platinum-induced nephrotoxicity is unknown. This prospective single-centre longitudinal cohort study evaluated long-term changes following treatment in childhood.
METHODS: 63 children treated with platinum (27 cisplatin, 24 carboplatin and 12 both) were studied at the end of treatment (End), 1 year and 10 years later. No child received ifosfamide. Glomerular filtration rate (GFR), serum calcium and magnesium (Mg) were measured, and total nephrotoxicity score (N(s)) was graded.
RESULTS: There was no significant overall change in renal function over time in any treatment group (cisplatin, carboplatin or combined). Apart from marginally reduced median GFR (84 ml/min/1.73 m(2)) and Mg (0.68 mmol/l) at End of cisplatin, median GFR, Ca and Mg were normal at all times in each group. At 10 years, GFR was <60 ml/min/1.7 3m(2) in 11%, N(s) grade was severe in 15% and oral Mg supplements were required in 7% cisplatin patients. After cisplatin, older age at treatment was correlated with lower GFR at 10 years (p=0.005), and higher N(s) at End and 10 years (both p=0.02). After carboplatin treatment, older age was associated with lower GFR at all times, and with higher N(s) at End and 1 year (all p<0.03). Higher cisplatin dose rate (>40 mg/m(2)/day) was associated with higher N(s) at 1 year (p=0.02) and higher carboplatin dose with lower Mg at 1 year and with higher N(s) at 1 and 10 years (all p<0.008).
CONCLUSIONS: Platinum nephrotoxicity did not change significantly over 10 years. Its severity was correlated to older age at treatment, and at some time points to higher cisplatin dose rate and higher cumulative carboplatin dose.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19850470     DOI: 10.1016/j.ejca.2009.06.032

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  44 in total

1.  Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.

Authors:  Kelly R McMahon; Maya Harel-Sterling; Michael Pizzi; Louis Huynh; Erin Hessey; Michael Zappitelli
Journal:  Pediatr Nephrol       Date:  2018-09-14       Impact factor: 3.714

2.  Treatment of childhood astrocytomas with irinotecan and cisplatin.

Authors:  J Mora; S Perez-Jaume; O Cruz
Journal:  Clin Transl Oncol       Date:  2017-08-21       Impact factor: 3.405

3.  A Population Pharmacokinetic Model of Gentamicin in Pediatric Oncology Patients To Facilitate Personalized Dosing.

Authors:  C C Llanos-Paez; C E Staatz; R Lawson; S Hennig
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

4.  Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors.

Authors:  Sebastiaan L Knijnenburg; Monique W Jaspers; Helena J van der Pal; Antoinette Y Schouten-van Meeteren; Antonia H Bouts; Jan A Lieverst; Arend Bökenkamp; Caro C E Koning; Foppe Oldenburger; James C H Wilde; Flora E van Leeuwen; Huib N Caron; Leontien C Kremer
Journal:  Clin J Am Soc Nephrol       Date:  2012-07-19       Impact factor: 8.237

5.  Platinum compounds and sodium metabolism in children with diencephalic glioma.

Authors:  N Puma; A Ruggiero; M Scalzone; P Coccia; S Triarico; G Trombatore; S Mastrangelo; R Riccardi
Journal:  J Neurooncol       Date:  2013-07-10       Impact factor: 4.130

6.  Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment.

Authors:  Moshe Rogosnitzky; Milton J Finegold; Patricia J McLaughlin; Ian S Zagon
Journal:  Invest New Drugs       Date:  2012-12-30       Impact factor: 3.850

Review 7.  Developing better mouse models to study cisplatin-induced kidney injury.

Authors:  Cierra N Sharp; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-19

8.  Moderate aging does not exacerbate cisplatin-induced kidney injury or fibrosis despite altered inflammatory cytokine expression and immune cell infiltration.

Authors:  Cierra N Sharp; Mark Doll; Tess V Dupre; Levi J Beverly; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2018-11-28

9.  C57BL/6 mice require a higher dose of cisplatin to induce renal fibrosis and CCL2 correlates with cisplatin-induced kidney injury.

Authors:  Sophia M Sears; Cierra N Sharp; Austin Krueger; Gabrielle B Oropilla; Douglas Saforo; Mark A Doll; Judit Megyesi; Levi J Beverly; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2020-08-24

10.  Cisplatinum nephrotoxicity in oncology therapeutics: retrospective review of patients treated between 2005 and 2012.

Authors:  Morgan Finkel; Adam Goldstein; Yael Steinberg; Linda Granowetter; Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2014-08-30       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.